Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 4 | 2 | — | — | — | 5 |
Melanoma | D008545 | — | — | 4 | 3 | — | — | — | 5 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 4 | 1 | — | — | — | 4 |
Lymphoma | D008223 | — | C85.9 | 2 | 2 | — | — | — | 3 |
B-cell lymphoma | D016393 | — | — | 2 | 2 | — | — | — | 3 |
Recurrence | D012008 | — | — | — | 2 | — | — | — | 2 |
Burkitt lymphoma | D002051 | — | C83.7 | 1 | 1 | — | — | — | 2 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | 2 | — | — | — | 2 |
Adenocarcinoma | D000230 | — | — | 1 | 1 | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 3 | — | — | — | — | 3 |
Neoplasms | D009369 | — | C80 | 3 | — | — | — | — | 3 |
Kidney diseases | D007674 | EFO_0003086 | N08 | 2 | — | — | — | — | 2 |
Urologic neoplasms | D014571 | — | C64-C68 | 2 | — | — | — | — | 2 |
Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 2 | — | — | — | — | 2 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 2 | — | — | — | — | 2 |
Urologic diseases | D014570 | — | N39.9 | 2 | — | — | — | — | 2 |
Neoplasms by histologic type | D009370 | — | — | 2 | — | — | — | — | 2 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | — | — | — | — | 2 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | — | — | — | — | 1 |
Drug common name | VARLILUMAB |
INN | varlilumab |
Description | Varlilumab (human mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3137347 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 0125DUV5XC (ChemIDplus, GSRS) |